Radiopharm Theranostics Ltd (ASX: RAD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Radiopharm Theranostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $18.84 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 4.71 billion
Earnings per share -0.018
Dividend per share N/A
Year To Date Return -88.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Radiopharm Theranostics Ltd (ASX: RAD)
    Latest News

    Scientists in a laboratory look at a computer screen with anticipation on their faces.
    Healthcare Shares

    This biotechnology stock just ticked over 100% gains for the month on more good news

    Two drug development agreements in under a month have caused this junior biotech's shares to surge.

    Read more »

    A boy stands firm on a rocky cliff holding a rocket in each hand and looking up toward the sky, anticipating flying into space.
    Small Cap Shares

    2 ASX small-cap shares rocketing 35% to 54% today

    Two soaring ASX small-cap shares are setting the bar high on Friday.

    Read more »

    One hundred dollar notes planted in the ground, representing ASX growth shares.
    Small Cap Shares

    'Richest pipeline' in ASX: Expert names 3 small-cap shares to buy

    Ask A Fund Manager: Alto Capital's Tony Locantro also reveals what his biggest regret in investing is.

    Read more »

    RAD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Radiopharm Theranostics Ltd

    Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

    RAD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Nov 2026 $0.00 $0.00 0.00% 1,666,666 $0.00 $0.00 $0.00
    19 Nov 2026 $0.00 $0.00 0.00% 11,419,577 $0.00 $0.00 $0.00
    18 Nov 2026 $0.00 $0.00 0.00% 1,816,011 $0.00 $0.00 $0.00
    17 Nov 2026 $0.00 $0.00 0.00% 21,752,520 $0.00 $0.00 $0.00
    16 Nov 2026 $0.00 $0.00 0.00% 1,248,716 $0.00 $0.00 $0.00
    13 Nov 2026 $0.00 $0.00 0.00% 468,690 $0.00 $0.00 $0.00
    12 Nov 2026 $0.00 $0.00 0.00% 623,785 $0.00 $0.00 $0.00
    11 Nov 2026 $0.00 $0.00 0.00% 20,184,407 $0.00 $0.00 $0.00
    10 Nov 2026 $0.00 $0.00 0.00% 3,796,694 $0.00 $0.00 $0.00
    09 Nov 2026 $0.00 $0.00 0.00% 26,084,275 $0.00 $0.00 $0.00
    06 Nov 2026 $0.00 $0.00 0.00% 3,493,295 $0.00 $0.00 $0.00
    05 Nov 2026 $0.00 $0.00 0.00% 6,115,697 $0.00 $0.00 $0.00
    04 Nov 2026 $0.00 $0.00 0.00% 11,288,609 $0.00 $0.00 $0.00
    03 Nov 2026 $0.00 $0.00 0.00% 24,480,673 $0.00 $0.00 $0.00
    02 Nov 2026 $0.01 $0.00 0.00% 10,433,448 $0.01 $0.01 $0.00
    30 Oct 2026 $0.01 $0.00 0.00% 66,268 $0.00 $0.01 $0.00
    29 Oct 2026 $0.00 $0.00 0.00% 74,363 $0.00 $0.00 $0.00
    28 Oct 2026 $0.00 $0.00 0.00% 123,285 $0.00 $0.00 $0.00
    27 Oct 2026 $0.00 $0.00 0.00% 12,107,871 $0.00 $0.00 $0.00
    26 Oct 2026 $0.01 $0.00 0.00% 2,918,823 $0.00 $0.01 $0.00
    23 Oct 2026 $0.00 $0.00 0.00% 541,452 $0.00 $0.00 $0.00
    22 Oct 2026 $0.00 $0.00 0.00% 6,779,489 $0.00 $0.00 $0.00
    21 Oct 2026 $0.00 $0.00 0.00% 3,017,597 $0.00 $0.00 $0.00

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    09 Nov 2026 Paul Hopper Sell 1,111,111 $3,333
    As advised by the company. Sale of Shares
    05 Nov 2026 Bruce Goodwin Sell 1,111,111 $3,913
    As advised by the company. Sale of Shares
    05 Nov 2026 Ian Turner Sell 1,111,111 $3,913
    As advised by the company. Sale of Shares
    05 Nov 2026 Riccardo Canevari Sell 1,555,556 $5,494
    As advised by the company. Sale of Shares
    16 Oct 2026 Ian Turner Cancelled 1,111,111 $4,444
    Cancellation of securities.
    16 Oct 2026 Riccardo Canevari Cancelled 1,555,556 $6,222
    Cancellation of securities.
    16 Oct 2026 Bruce Goodwin Cancelled 1,111,111 $4,444
    Cancellation of securities.
    16 Oct 2026 Paul Hopper Cancelled 1,111,111 $4,444
    Cancellation of securities.
    30 Sep 2026 Riccardo Canevari Expiry 24,000,000 $144,000
    Options expired.
    17 Sep 2026 Ian Turner Issued 1,222,222 $10,999
    Participation in share purchase plan. AUD 0.009 per Share
    17 Sep 2026 Riccardo Canevari Issued 3,888,889 $35,000
    Participation in share purchase plan.
    17 Sep 2026 Ian Turner Issued 1,555,556 $14,000
    Participation in share purchase plan. AUD 0.009 per Share
    17 Sep 2026 Riccardo Canevari Issued 3,888,889 $27,222
    Participation in share purchase plan.
    17 Sep 2026 Ian Turner Issued 2,777,778 $19,444
    Participation in share purchase plan.
    17 Sep 2026 Bruce Goodwin Issued 2,777,778 $25,000
    Participation in share purchase plan.
    17 Sep 2026 Bruce Goodwin Issued 2,777,778 $19,444
    Participation in share purchase plan.
    17 Sep 2026 Paul Hopper Issued 2,777,778 $19,444
    Participation in share purchase plan.
    17 Sep 2026 Paul Hopper Issued 2,777,778 $25,000
    Participation in share purchase plan.
    24 Aug 2026 Riccardo Canevari Expiry 1,875,000 $20,625
    Options expired.
    24 Aug 2026 Hester Larkin Expiry 275,000 $3,025
    Options expired.
    24 Aug 2026 Paul Hopper Expiry 27,500,000 $302,500
    Options expired.
    24 Aug 2026 Ian Turner Expiry 1,875,000 $20,625
    Options expired.
    25 Mar 2026 Ian Turner Buy 730,000 $13,870
    On-market trade.
    12 Dec 2025 Paul Hopper Issued 18,142,000 $344,698
    Issue of options. Non-cash
    12 Dec 2025 Ian Turner Issued 6,814,000 $129,466
    Issue of options. Non cash
    12 Dec 2025 Riccardo Canevari Issued 74,338,000 $1,412,422
    Issue of options. Non-cash options
    25 Nov 2025 Ian Turner Expiry 1,900,002 $39,900
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Paul Alex Hopper Executive ChairmanFounderExecutive Director Feb 2021
    Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare companies in Australia and the United States. Mr Hopper founded and has been involved with a number of biotechnology and healthcare companies. His experience includes corporate management, business development, company funding, and commercial activities within the healthcare and life sciences sectors. Mr Hopper has also been involved in corporate transactions and the development of biotechnology businesses across a range of markets.
    Mr Ian Turner Non-Executive Director Apr 2021
    Mr Turner has experience in the nuclear medicine, radiopharmaceutical and radiochemical sectors. Mr Turner held management roles within radiopharmaceutical manufacturing and distribution businesses, including organisations involved in radioisotope production and nuclear medicine services. His experience includes business management, manufacturing operations, supply chain activities and commercial development within the radiopharmaceutical industry. Since 2013, Mr Turner has provided advisory services relating to acquisition opportunities and business development activities in the fields of nuclear medicine, radiochemicals and radiopharmaceuticals.
    Mr Riccardo Canevari Chief Executive OfficerManaging Director Sep 2021
    Mr Canevari has experience in the pharmaceutical, radiopharmaceutical and nuclear medicine sectors. He worked with Advanced Accelerator Applications, where his responsibilities included commercial strategy and oversight of country operations across North America, Europe and Asia. Prior to this, Mr Canevari held roles within Novartis Oncology and Novartis Pharma. His experience includes commercial management, business development, product strategy and operational management across international markets. He has also held management roles with Ethicon and Johnson & Johnson.
    Ms Hester Larkin Non-Executive Director Feb 2022
    Ms Larkin has experience in the diagnostic imaging, pharmaceutical and biotechnology sectors. Since 2008, she has provided consulting services across projects ranging from pre-clinical and clinical development through to regulatory submissions, medical advisory activities, manufacturing arrangements and commercial partnerships. Prior to this, Ms Larkin held management roles with Bristol-Myers Squibb and DuPont Pharmaceuticals. Her experience includes business development, commercial management, marketing and operational activities across European and international markets.
    Mr Noel Donnelly Non-Executive Director Oct 2024
    Mr Donnelly has experience in finance, research and development, strategy, portfolio management, financial planning and analysis, project management, business partnering, valuation and decision-support analysis. Mr Donnelly has held finance and operational roles within the biotechnology and pharmaceutical sectors. His experience includes financial management, research and development operations, portfolio management, project evaluation and cross-functional team leadership. Prior to joining the Company, Mr Donnelly held roles with PEPGEN, EIP Pharma and Takeda/Shire, where he was involved in finance, business operations and research and development activities.
    Mr Bruce Goodwin Non-Executive Director Nov 2025
    Mr Goodwin has experience across the health sector in Australia and the United States. Mr Goodwin has worked in sales and marketing, finance, business development and operational management roles. His experience includes strategic planning, business development, organisational management and advisory services within the biopharmaceutical, medical device and healthcare sectors. Prior to this, Mr Goodwin held leadership roles within the healthcare industry and was involved in the management of operations across multiple countries.
    Mr Nathan Kim -liung Jong Joint Company Secretary
    -
    Ms Amritha Sushil Joint Company Secretary May 2026
    -
    Aaron Laurita CFO
    -
    Dimitris Voliotis Chief Medical Officer
    -
    Nathan Kim -liung Jong Joint Company Secretary
    -
    Amritha Sushil Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    BNP Paribas Nominees Pty Ltd 1,487,980,800 34.30%
    Lantheus Omega LLC Wholly Owned Subsidiary Of Lantheus Holdings Inc 537,958,513 12.40%
    HSBC Custody Nominees 203,065,059 4.68%
    UBS Nominees Pty Ltd 153,352,695 3.54%
    BNP Paribas Noms Pty Ltd 138,052,666 3.18%
    J P Morgan Nominees Australia Pty Limited 124,195,099 2.86%
    Adman Lanes Pty Ltd 121,097,581 2.79%
    Morgan Stanley Australia Securities (Nominee) Pty Limited 116,947,117 2.70%
    Citicorp Nominees Pty Limited 100,285,151 2.31%
    NM Investment Limited 94,858,929 2.19%
    Kilinwata Investments Pty Ltd 93,571,428 2.16%
    HSBC Custody Nominees (Australia) Limited (I) 68,861,998 1.59%
    Dulyne Pty Ltd 52,500,000 1.21%
    Paul Hopper 52,400,000 1.21%
    HSBC Custody Nominees (Australia) Limited (II) 30,200,971 0.70%
    Palm Beach Nominees Pty Limited 29,296,829 0.68%
    Mr Heng Chen 24,919,395 0.57%
    Scarlett Hopper 23,857,142 0.55%
    BNP Paribas Nominees Pty Ltd (i) 20,099,840 0.46%
    Shared Office Services Pty Ltd 15,839,358 0.37%

    Profile

    since

    Note